Cardiac Allograft Vasculopathy Inhibition with Alirocumab

Not Recruiting

Trial ID: NCT03537742

Age - 18 Years-N/A Condition - Pediatric Transplantation, Pediatric Cardiology Gender - ALL Accepting Healthy Volunteers - No

Purpose

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Official Title

PCSK9 Inhibition After Heart Transplantation

Stanford Investigator(s)

William Fearon, MD
William Fearon, MD

Professor of Medicine (Cardiovascular Medicine)

Eligibility

Inclusion Criteria:

* Heart Transplant recipient

Exclusion Criteria:

* impaired liver function

View More
View Less

Intervention(s):

biological: alirocumab

biological: placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Study Team
650-724-2883

©2025 Stanford Medicine